This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Immune Network Ltd.
Drug Names(s): V5 Immunitor
Description: V5 is derived from pooled blood of hepatitis B and C carriers by employing Immunitor's proprietary technology. The process of manufacturing involves heat- and chemical inactivation with subsequent formulation into a tablet.
V5 is currently approved in Ukraine as an immunomodulating supplement.
Deal Structure: V5 was originally developed by Immunitor.
In September 2010, Immune Network entered into a letter of intent to acquire Immunitor oral vaccine technology and products.
Pink Sheet COVID-19 Pipeline Tracker
Additional information available to subscribers only: